Not provided
Not provided
Not provided
Not provided
Not provided
Business decision - not related to product quality or safety concerns
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Some people with diabetes get foot ulcers that do not heal. These ulcers can get infected and cause other medical problems.
Five patients with these foot ulcers volunteered to participate in the first part of this study (C9T12015, NCT02657876). They are called Cohort 1 in this registration. Cohort 1 received one application (piece) of an experimental skin tissue to make sure it was safe.
This study will extend the safety test of the experimental skin tissue. It will find out if it is safe to use more than once to cover non-healing ulcers.
This extension will include two more groups, Cohort 2 and Cohort 3. Cohort 2 may get up to 5 applications. Cohort 3 may get up to 10 applications. The number of applications will depend on how well the wound is healing.
Participants will be in the study up to one year.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort 1: One Application | Experimental | Participants enrolled in Cohort 1 received one application of experimental skin tissue during the first part of this trial (NCT02657876) |
|
| Cohort 2: Up to Five Applications | Experimental | Participants enrolled in Cohort 2 may receive up to 5 applications of experimental skin tissue as required for wound healing |
|
| Cohort 3: Up to Ten Applications | Experimental | Participants enrolled in Cohort 3 may receive up to 10 applications of experimental skin tissue as required for wound healing |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ExpressGraft-C9T1 Skin Tissue | Biological | A round patch of experimental skin tissue that the doctor applies over the ulcer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with adverse events at Week 12 | Clinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events | at Week 12 |
| Number of participants with adverse events through study completion | Clinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events | at approximately 12 months |
Not provided
Not provided
Volunteers will be consented. Then there will be a run-in period for the doctor to run some tests. If the tests show the study would be good for the patient, the doctor will enroll them as participants in the trial.
Inclusion Criteria:
To be considered for inclusion, a participant:
Exclusion Criteria:
The doctor may not consider for inclusion a participant who:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Leader | Stratatech, a Mallinckrodt Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Titan Clinical Research | Phoenix | Arizona | 85004 | United States | ||
| Limb Preservation Platform, Inc. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D017719 | Diabetic Foot |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Cohort 2 will begin when the study starts, and after the safety monitoring board approves progression to the next cohort, Cohort 3 will begin.
Not provided
Not provided
Not provided
Not provided
|
| Fresno |
| California |
| 93710 |
| United States |
| Center For Clinical Resarch | San Francisco | California | 94115 | United States |
| Center for Advanced Research & Education | Gainesville | Georgia | 30501 | United States |
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D016523 | Foot Ulcer |
| D007871 | Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D003929 | Diabetic Neuropathies |